Log in | Register

Allergan Fourth Quarter Profit Grows 51% as Sales Climb

For the latest pharmaceutical news and updates - Sign up now!
Loading...

IRVINE, Calif. (AP) — Botox maker Allergan Inc. said Thursday its profit jumped 51 percent in the fourth quarter, but its forecasts for 2010 trended below Wall Street estimates.

In the fourth quarter, Allergan said its profit grew to $221.5 million, or 72 cents per share, from $146.6 million, or 48 cents per share. Excluding one-time items the company said it earned 78 cents per share.

Revenue rose 16 percent, to $1.22 billion from $1.06 billion.

Analysts expected a profit of 77 cents per share and $1.16 billion in revenue, according to Thomson Reuters.

The company said drug revenue grew 18 percent and medical device sales rose 8 percent.

For the full year, Allergan's profit climbed to $621.3 million, or $2.03 per share, from $223.4 million, or $1.84 per share. Revenue rose to $4.5 billion from $4.4 billion.

For 2010, Allergan forecast an adjusted profit of $3.09 to $3.15 per share and $4.55 billion to $4.75 billion in sales.

Analysts expected earnings of $3.15 per share — at the high end of the company's forecast — on higher revenue of $4.78 billion.

The company's forecast includes $3.78 billion to $3.93 billion in specialty drug sales and $770 million to $820 million in medical device revenue. The company is expecting $1.33 billion to $1.37 billion in Botox revenue.

For the first quarter, Allergan is calling for a profit of 57 cents to 59 cents per share on $1.06 billion to $1.1 billion in revenue. Analysts estimated 68 cents per share and $1.11 billion in revenue.

 

Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Lung Cancer Drug Treats Rare Lymphoma Tumors

Lung Cancer Drug Treats Rare Lymphoma Tumors

May 17 | Video

A new study found Xalkori effective in treating anaplastic lymphoma among children, an encouraging development for gene-targeted therapy.

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter